News

Under the license agreement, Presidio becomes responsible for all further development and commercialization activities and costs relating to the program. XTL will receive an upfront payment of $4

The recall decision resulted from the ongoing monitoring of marketed product, which revealed a deviation from the approved product specification. As a result, there will be an out-of-stock

This patent family, owned exclusively by Alnylam, covers fundamental aspects of the structure and uses of RNAi products including their use to mediate RNAi in mammalian cells and

The open-label study, which was authorized by the Japan’s Pharmaceutical and Medical Device Administration (PMDA), over-enrolled a total of 29 patients. The patients will be treated with Soliris

The newly issued patent includes claims covering both composition of matter of PX-867 and pharmaceutical preparations containing PX-867. The preclinical development for PX-867 has focused on cardiovascular disease.

Michael Kauffman, CEO of Epix, said: “While PRX-00023 continued to show a highly desirable safety and tolerability profile, we are disappointed in the overall results observed in our

The lower doses are believed to be more physiologically relevant. The data showed that the rate of absorption of B12 administered with eligen increased significantly 26 to 34

The Phase I trial is a single center, open label study, designed to evaluate safety, distribution and dosimetry of BFPET as a PET tracer for myocardial perfusion imaging

In collaboration with doctors from University of California, San Diego (UCSD) School of Medicine, Bennu plans to initiate a Phase IIa clinical study of delayed release cysteamine (DR